Home › Mantle Cell Lymphoma › Virginia › Richmond
Mantle Cell Lymphoma clinical trials in Richmond, VA
4 studies for Mantle Cell Lymphoma are looking for participants at sites in and around Richmond (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
RecruitingPhase 3
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
- Vcu Massey Cancer Center, Richmond
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Virginia Commonwealth University Massey Cancer Center, Richmond
A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
- Massey Cancer Center, Richmond
Mantle Cell Lymphoma trials in other cities
- Baldwin Park, CA15 studies
- Houston, TX15 studies
- Durham, NC13 studies
- Seattle, WA12 studies
- Milwaukee, WI12 studies
- New York City, NY12 studies
- Boston, MA11 studies
- Columbus, OH11 studies
- Nashville, TN11 studies
- Chicago, IL10 studies
- Portland, OR9 studies
- Rochester, MN9 studies
Other studies in Richmond
- Breast Cancer26 studies
- Non-Small Cell Lung Cancer25 studies
- Prostate Cancer19 studies
- Heart Failure16 studies
- Lung Cancer14 studies
- Colorectal Cancer13 studies
- Cardiovascular Disease13 studies
- Steatotic Liver Disease12 studies
- Acute Myeloid Leukemia12 studies
- Head and Neck Squamous Cell Carcinoma12 studies
- Metastatic Cancer12 studies
- Melanoma11 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.